Botanix Investor Centre

Botanix is an ASX-listed company (ASX:BOT), in a prime position for growth and to return value for shareholders. With deep expertise in dermatology and pharmaceutical product commercialisation, we are on track to disrupt some of the most lucrative global healthcare markets.

ASX: BOT | Share price


Change

Feb 4, 2021
April 6, 2017
December 9, 2019
September 17, 2019
January 31, 2019
November 15, 2018
August 13, 2018
April 9, 2018
November 13, 2017

Latest video

Quarterly Activities Report and 4C Quarterly Cash Flow Report

Botanix (ASX:BOT) has today published its Quarterly Activities…

BOT Video | Not To Be Missed

Botanix has united three experts to explain why its lead product,…

JP Morgan Healthcare Conference Presentation

Botanix will be attending the JP Morgan Healthcare Conference…

Research Report by Euroz Hartleys – 8 December 2022

Botanix is pleased to share an analyst report published by Euroz…

FDA confirmation Sofpironium Bromide NDA is formally under review

Botanix has today announced that it has received formal written…

SPP Now Open

Botanix’s recently announced Share Purchase Plan (SPP) to…

A$5 million strategic Placement + Share Purchase Plan

Botanix (ASX:BOT) has today lifted its trading halt, sharing…

Significant R&D Tax Incentive Refund

Botanix has today announced it has received a Research and Development…

Check out our latest investor presentation

Sign up to receive our latest news

Processing...
Thank you! Your subscription has been confirmed. You'll hear from us soon.
ErrorHere